Howard Barnebey, MD
Ophthalmology · Bellevue, WANPI 1346206224
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.1%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Aerie Pharmaceuticals, Inc. at 39.3% of the total. Reporting peaked in 2019 at $17,501 and has fallen 54.5% since, to $7,959 in 2025. Among ophthalmology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 279 payments — averaging $189.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aerie Pharmaceuticals, Inc.$21K
- Bausch & Lomb Americas Inc.$9K
- Glaukos Corporation$8K
- Alcon$6K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$5K
- Nidek CO., LTD.$2K
- plus $2K from 15 others
Across 16 payments — averaging $595.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$7K
- Glaukos Corporation$2K
What the payments were for
- Consulting fees$6,00011%
- Speaking & faculty fees$28,11253%
- Travel & lodging$5,61711%
- Food & beverage$12,96825%
- Education$450%
- Gifts$450%
- Entertainment$1420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aerie Pharmaceuticals, Inc. | 32 | $20,797 |
| Bausch & Lomb Americas Inc. | 22 | $8,648 |
| Glaukos Corporation | 55 | $8,483 |
| Alcon | 83 | $5,739 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 22 | $5,308 |
| Nidek CO., LTD. | 1 | $2,000 |
| AbbVie(2 entities) | 36 | $497 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $282 |
| NEW World Medical,inc. | 4 | $238 |
| Sight Sciences, Inc. | 5 | $186 |
| Dompe US, Inc. | 2 | $152 |
| Ivantis, Inc | 1 | $136 |
| Topcon Healthcare, Inc. | 2 | $126 |
| Optos, Inc. | 1 | $110 |
| Rayner Intraocular Lenses Limited | 2 | $56 |
| Eyevance Pharmaceuticals LLC | 1 | $37 |
| Novartis | 1 | $33 |
| Optos PLC | 1 | $33 |
| Omeros Corporation | 1 | $29 |
| Kala Pharmaceuticals, Inc. | 1 | $27 |
| Akorn, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rhopressa$20,250
- Rocklatan$20,250
- VYZULTA$13,196
- PRESERFLO MicroShunt$3,979
- iDose$1,950
- Clareon$690
- iPRIME Viscodelivery System$650
- AcrySof IQ PanOptix UV IOL$640
- iStent inject W$464
- AcrySof IQ PanOptix$455
- Clareon PanOptix Pro$435
- ORA$427
- ARGOS$335
- Acrysof, IQ ReSTOR$250
- OCT OPHTHALMOSCOPE$219
- PANORAMIC OPHTHALMOSCOPE$219
- iStent Infinite$176
- iDoseTR$176
- iStent$161
- KXL System$161
How this compares
$52,930 in reported general payments places this provider in the 95th percentile of 428 ophthalmology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyzultaLatanoprostene Bunod | 231 | $122,703 |
| RhopressaNetarsudil Mesylate | 186 | $115,990 |
| LumiganBimatoprost | 196 | $114,847 |
| XiidraLifitegrast | 41 | $65,133 |
| RestasisCyclosporine | 35 | $40,996 |
| Alphagan PBrimonidine Tartrate | 83 | $40,982 |
| Travoprost | 218 | $37,337 |
| Brinzolamide | 155 | $35,966 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 98 | $25,286 |
| Brimonidine Tartrate | 202 | $24,860 |
| CombiganBrimonidine Tartrate/Timolol | 39 | $22,549 |
| RocklatanNetarsudil Mesylat/Latanoprost | 33 | $19,082 |
| AzoptBrinzolamide | 34 | $16,489 |
| Travatan ZTravoprost | 25 | $15,056 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 54 | $13,443 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Alphagan P, Combigan | $497 | $219,374353 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $8,648 | $187,835272 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $20,797 | $135,072219 claims |
| AlconSimbrinza, Azopt | $5,739 | $41,775132 claims |
| NovartisTravatan Z | $33 | $15,05625 claims |
| Akorn, Inc.Zioptan | $12 | $9,85815 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $5,308 | $3,16426 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 428 ophthalmology providers in Washington.
Other ophthalmology in Bellevue
- Audrey RostovBellevue$155K
- David SapersteinBellevue$54K
- Mary CodayBellevue$10K
- Stephanie HsuBellevue$6K
- Laura PerimanSeattle$1.7M
- Sheldon CowenSeattle$560K
- Todd SchneidermanSilverdale$200K
- Jennifer ChaoSeattle$188K
- Mark KontosSpokane Valley$175K
- John SamplesOlympia$115K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.